{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P26651",
      "entity_text" : "TTP",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P06400",
      "entity_text" : "RB 1",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Smith RB 1, Swartzentruber GS 2, Richardson WH 1,3 1 Palmetto Health Richland, Columbia, SC, USA; 2 University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 3 Palmetto Poison Center, Columbia, SC, USA Background : Intravenous injection of reformulated Opana ER (R) has recently been described to cause hemolytic anemia and thrombotic thrombocytopenic purpura (TTP) in a 2012 report by the Tennessee Department of Health.",
  "reading_complete" : "2020-08-04T13:24:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T13:06:39Z",
  "trigger" : "cause",
  "evidence" : [ "RB 1 , Swartzentruber GS 2 , Richardson WH 1,3 \n\n 1 Palmetto Health Richland, Columbia, SC, USA; 2 University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 3 Palmetto Poison Center, Columbia, SC, USA\n\nBackground: Intravenous injection of reformulated Opana ER(R) has recently been described to cause hemolytic anemia and thrombotic thrombocytopenic purpura (TTP" ],
  "pmc_id" : "3951637",
  "score" : 0
}